BLAINJECTIONINJECTABLE
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
19
Data completeness
4/8 — Partial
SAPHNELO (anifrolumab-fnia) by AstraZeneca is type i interferon receptor antagonists [moa]. First approved in 2021.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAPHNELO (anifrolumab-fnia) is a monoclonal antibody that antagonizes the Type I Interferon receptor, approved by the FDA on July 30, 2021. It is indicated for the treatment of systemic lupus erythematosus (SLE) by blocking Type I interferon signaling, a key driver of lupus pathogenesis. The drug represents a novel mechanism targeting the interferon pathway, differentiating it from traditional immunosuppressants and biologic therapies in the SLE treatment landscape.
$0.0BPart D
Mechanism of Action
Type I Interferon Receptor Antagonists
Pharmacologic Class:
Type I Interferon Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (19)
Saphnelo Use in Females of Child-bearing Potential
Started Oct 2026
26,000,000 enrolled
Systemic Lupus Erythematosus
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Started Apr 2026
245 enrolled
Systemic Lupus Erythematosus
NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care
Started Mar 2026
125 enrolled
Lupus Erythematosus, Systemic
Anifrolumab Pregnancy Study
Started Jan 2026
627 enrolled
Systemic Lupus Erythematosus
Anifrolumab Malignancy and Serious Infections Study
Started Jan 2026
3,195 enrolled
Systemic Lupus Erythematosus
Worked on SAPHNELO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.